Lipid nanoparticles deliver one-two punch to shrink resistant oral tumors in preclinical models
Researchers at the University of Pennsylvania have developed a lipid nanoparticle platform to deliver mRNA therapies directly to oral squamous cell carcinoma. This new method aims to improve treatment efficacy for head and neck cancers while potentially triggering a systemic immune response against metastasis.
Why it matters
This innovation could significantly improve survival rates and quality of life for oral cancer patients by providing a more targeted alternative to traditional surgery and radiation.
by Deborah Stull, University of Pennsylvania
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Overview of the lipid nanoparticle (LNP) co-delivery platform. Credit: Advanced Materials (2026). DOI: 10.1002/adma.73721 Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer, and the number of new cases is predicted to rise by 30% in the next decade. Despite decades of cancer research, treating OSCC remains a challenge. The five-year survival rate is approximately 50%, and standard treatments such as ablative surgery and radiation often leave patients with permanent disfigurement or profound, lifelong impairment of essential oral functions such as speaking and swallowing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in